Thrombocytopenia after Dupilumab for the Treatment of Atopic Dermatitis

Abstract

Get full access to this article

View all access options for this article.

References

Available at: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/dupixent-dupilumabe-ampliacao-de-uso

Aoki

, Lorenzini

, Orfali

, et al. Consensus on the therapeutic management of atopic dermatitis—Brazilian Society of Dermatology. An Bras Dermatol, 2019; 94(2 Suppl 1):S67–S75.

Wollemberg

, Beck

, Blauvelt

, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol, 2020; 182:1120–1135.

Arnold

, Nazi

, Warkentin

, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev, 2013; 27(3):137–145.

Frey

, Kendziora

, Holch

, et al. Immune thrombocytopenic purpura in a patient with atopic dermatitis treated with dupilumab. Acta Derm Venereol, 2021; 101:adv00409. doi: 10.2340/00015555-3734

Rutherford

, Tran

, Salazar

, et al. An uncharacteristic presentation of Evans syndrome following treatment with dupilumab. Cureus, 2021; 27;13(7):e16658.